AdvisorShares Investments LLC lifted its position in Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) by 115.5% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 206,716 shares of the company's stock after buying an additional 110,774 shares during the quarter. AdvisorShares Investments LLC's holdings in Bright Minds Biosciences were worth $314,000 at the end of the most recent quarter.
Separately, Checchi Capital Advisers LLC acquired a new position in Bright Minds Biosciences during the 4th quarter worth $45,000. Institutional investors own 7.70% of the company's stock.
Get Bright Minds Biosciences alerts:Bright Minds Biosciences Price Performance
DRUG opened at $0.91 on Friday. Bright Minds Biosciences Inc. has a 12 month low of $0.75 and a 12 month high of $8.95. The business has a fifty day moving average price of $0.93 and a 200 day moving average price of $1.40.
Bright Minds Biosciences (NASDAQ:DRUG – Get Rating) last released its earnings results on Monday, May 16th. The company reported ($0.30) EPS for the quarter.About Bright Minds Biosciences
(Get Rating)
Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Further Reading
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
Want to see what other hedge funds are holding DRUG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating).
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.